Robert Byington's research topics

Robert Byington

Concepts (112)

Back to Profile

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name	Number of Publications	Most Recent Publication	Publications by All Authors	Concept Score	Why?
Diabetes Mellitus, Type 2	16	2017	1437	0.970	Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors	7	2017	167	0.790	Why?
Cardiovascular Diseases	11	2017	1158	0.700	Why?
Hypoglycemic Agents	6	2013	186	0.410	Why?
Simvastatin	2	2013	26	0.340	Why?
Diabetic Angiopathies	5	2013	150	0.310	Why?
Pravastatin	3	2004	16	0.310	Why?
Coronary Disease	3	2007	226	0.290	Why?
Randomized Controlled Trials as Topic	11	2010	541	0.280	Why?
Antihypertensive Agents	5	2015	363	0.240	Why?
Diabetes Mellitus, Type 1	1	2008	267	0.240	Why?
Heart Diseases	2	2008	114	0.230	Why?
Stroke	5	2011	691	0.230	Why?
Blood Pressure	3	2015	861	0.200	Why?
Middle Aged	17	2017	11851	0.190	Why?
Progestins	1	2002	27	0.190	Why?
Aged	16	2017	10263	0.180	Why?
Carotid Artery Diseases	1	2002	126	0.180	Why?
Estrogens	1	2002	194	0.170	Why?
Follow-Up Studies	7	2017	2240	0.170	Why?
Postmenopause	1	2002	424	0.160	Why?
Female	18	2017	19945	0.160	Why?
Drug Therapy, Combination	5	2017	292	0.160	Why?
Dyslipidemias	2	2017	60	0.150	Why?
Humans	24	2017	32282	0.140	Why?
Male	16	2017	19441	0.140	Why?
Triglycerides	2	2010	235	0.140	Why?
Hypertension	5	2015	979	0.130	Why?
Risk Factors	10	2017	3934	0.130	Why?
Proportional Hazards Models	5	2011	773	0.130	Why?
Angiotensin II Type 1 Receptor Blockers	1	2007	66	0.130	Why?
Angiotensin-Converting Enzyme Inhibitors	1	2007	133	0.120	Why?
Hypoglycemia	3	2013	43	0.120	Why?
Lipids	1	2017	253	0.120	Why?
Renin-Angiotensin System	1	2007	173	0.120	Why?
Treatment Outcome	7	2017	3416	0.120	Why?
Double-Blind Method	5	2017	565	0.110	Why?
Treatment Failure	3	2010	165	0.110	Why?
Fibroblast Growth Factors	1	2014	37	0.110	Why?
Hypertrophy, Left Ventricular	1	2015	122	0.110	Why?
Thiazolidinediones	1	2013	46	0.100	Why?
Cholesterol, HDL	1	2013	181	0.100	Why?
Diabetic Nephropathies	1	2014	223	0.100	Why?
Anticholesteremic Agents	2	2004	47	0.090	Why?
Myocardial Infarction	3	2011	466	0.090	Why?
Renal Insufficiency, Chronic	1	2014	293	0.090	Why?
Coronary Artery Disease	2	2007	427	0.090	Why?
Blood Glucose	5	2013	484	0.080	Why?
Sex Factors	2	2010	655	0.080	Why?
Multicenter Studies as Topic	2	2009	110	0.080	Why?
Patient Selection	2	2009	272	0.080	Why?
Research Design	2	2009	314	0.080	Why?
Lipid Metabolism	2	2013	108	0.080	Why?
Incidence	3	2014	1241	0.070	Why?
Prospective Studies	4	2014	2316	0.070	Why?
Cholesterol	1	2010	262	0.070	Why?
Cerebrovascular Disorders	1	2008	51	0.070	Why?
Adult	6	2013	9259	0.070	Why?
Cohort Studies	2	2009	1840	0.060	Why?
Cholesterol, LDL	1	2008	170	0.060	Why?
Disease Progression	2	2014	591	0.060	Why?
Aspirin	1	2004	59	0.050	Why?
Maternal Mortality	1	2003	9	0.050	Why?
Platelet Aggregation Inhibitors	1	2004	79	0.050	Why?
Age Factors	3	2013	1179	0.050	Why?
Prenatal Care	1	2003	54	0.050	Why?
Tunica Media	1	2002	39	0.050	Why?
Tunica Intima	1	2002	76	0.050	Why?
Amlodipine	1	2002	15	0.050	Why?
Calcium Channel Blockers	1	2002	53	0.050	Why?
Glomerular Filtration Rate	2	2014	302	0.040	Why?
Estrogen Replacement Therapy	1	2002	216	0.040	Why?
Time Factors	2	2017	2205	0.040	Why?
Multivariate Analysis	3	2010	651	0.040	Why?
Case-Control Studies	2	2014	854	0.030	Why?
Retrospective Studies	2	2017	3626	0.030	Why?
Sensitivity and Specificity	1	2007	556	0.030	Why?
Dose-Response Relationship, Drug	1	2017	717	0.030	Why?
Canada	1	2014	63	0.030	Why?
Risk Assessment	2	2014	1425	0.030	Why?
Up-Regulation	1	2014	193	0.030	Why?
Kidney	1	2014	521	0.020	Why?
Hypokalemia	1	2010	16	0.020	Why?
Hyperglycemia	1	2010	85	0.020	Why?
Creatinine	1	2010	191	0.020	Why?
Cause of Death	1	2010	236	0.020	Why?
Hyperlipidemias	1	2010	61	0.020	Why?
Feasibility Studies	1	2009	308	0.020	Why?
Harm Reduction	1	2008	15	0.020	Why?
Continental Population Groups	1	2009	228	0.020	Why?
Body Weight	1	2009	323	0.020	Why?
Life Style	1	2009	393	0.020	Why?
Ethnic Groups	1	2009	450	0.020	Why?
United States	1	2014	4072	0.010	Why?
Prognosis	1	2008	1534	0.010	Why?
Regression Analysis	1	2003	273	0.010	Why?
Reproducibility of Results	1	2005	757	0.010	Why?
Coronary Restenosis	1	2002	15	0.010	Why?
Time	1	2002	27	0.010	Why?
Cesarean Section	1	2003	114	0.010	Why?
Odds Ratio	1	2003	456	0.010	Why?
Muscular Diseases	1	2002	23	0.010	Why?
Demography	1	2002	101	0.010	Why?
Gastrointestinal Diseases	1	2002	50	0.010	Why?
Renal Insufficiency	1	2002	57	0.010	Why?
Liver Diseases	1	2002	72	0.010	Why?
Coronary Angiography	1	2002	159	0.010	Why?
Hypercholesterolemia	1	2002	73	0.010	Why?
Risk	1	2002	305	0.010	Why?
Comorbidity	1	2002	565	0.010	Why?
North Carolina	1	2003	1300	0.010	Why?
Breast Neoplasms	1	2002	762	0.010	Why?

Byington's Networks

Click the

Explore

buttons for more information and interactive visualizations!

Concepts (112)

Explore

Co-Authors (9)

Explore

Same Department

Explore

Physical Neighbors

Sisson, Caroline